Nektar Therapeutics (NKTR)
35.78
-1.94
(-5.14%)
USD |
NASDAQ |
Oct 16, 16:00
35.76
-0.02
(-0.06%)
After-Hours: 20:00
Nektar Therapeutics Cash from Investing (Quarterly) : -399.11M for June 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -399.11M |
| March 31, 2026 | -350.79M |
| December 31, 2025 | 0.372M |
| September 30, 2025 | -94.87M |
| June 30, 2025 | 49.62M |
| March 31, 2025 | 43.69M |
| December 31, 2024 | 60.21M |
| September 30, 2024 | 46.12M |
| June 30, 2024 | 16.98M |
| March 31, 2024 | 19.26M |
| December 31, 2023 | 17.38M |
| September 30, 2023 | 56.41M |
| June 30, 2023 | 25.17M |
| March 31, 2023 | 40.60M |
| December 31, 2022 | 40.01M |
| September 30, 2022 | 111.40M |
| June 30, 2022 | 84.15M |
| March 31, 2022 | 130.28M |
| December 31, 2021 | 120.20M |
| September 30, 2021 | -0.83M |
| June 30, 2021 | 72.95M |
| March 31, 2021 | 10.46M |
| December 31, 2020 | 92.74M |
| September 30, 2020 | 48.67M |
| June 30, 2020 | 157.04M |
| Date | Value |
|---|---|
| March 31, 2020 | 197.77M |
| December 31, 2019 | 135.48M |
| September 30, 2019 | 58.25M |
| June 30, 2019 | 25.29M |
| March 31, 2019 | -12.14M |
| December 31, 2018 | 87.54M |
| September 30, 2018 | -621.27M |
| June 30, 2018 | -894.42M |
| March 31, 2018 | 48.21M |
| December 31, 2017 | 22.98M |
| September 30, 2017 | -80.69M |
| June 30, 2017 | 41.97M |
| March 31, 2017 | -13.07M |
| December 31, 2016 | -142.10M |
| September 30, 2016 | 28.38M |
| June 30, 2016 | -4.923M |
| March 31, 2016 | 36.25M |
| December 31, 2015 | -7.205M |
| September 30, 2015 | -19.30M |
| June 30, 2015 | -65.99M |
| March 31, 2015 | 53.16M |
| December 31, 2014 | -24.81M |
| September 30, 2014 | 40.15M |
| June 30, 2014 | 5.302M |
| March 31, 2014 | -58.21M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Eli Lilly & Co. | -15.40B |
| Inovio Pharmaceuticals, Inc. | 6.147M |
| Tonix Pharmaceuticals Holding Corp. | -0.5769M |
| Capricor Therapeutics, Inc. | -48.76M |
| Kyntra Bio, Inc. | 17.67M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -75.77M |
| Cash from Financing (Quarterly) | 364.57M |
| Free Cash Flow | -234.03M |
| Free Cash Flow Per Share (Quarterly) | -2.295 |
| Free Cash Flow to Equity (Quarterly) | -68.37M |
| Free Cash Flow to Firm (Quarterly) | -68.66M |
| Free Cash Flow Yield | -26.96% |